ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Mar 2, 2016
Medtronic Expects to Generate $40 Billion in Free Cash Flow in Next 5 Years
Image Source: Medtronic. We continue to like Medtronic, and while shares are not necessarily cheap, we’re letting this big winner in the Dividend Growth Newsletter portfolio run. The company looks poised to generate a significant amount of free cash flow it can allocate to dividend growth in coming years.
Dec 4, 2015
Future Free Cash Flow to Drive Medtronic’s Dividend
Medtronic reported solid results in its fiscal second quarter. It continues to perform well as it integrates Covidien’s legacy operations.
Jun 22, 2015
Dividend Increases for the Week Ending June 19
Let's take a look at companies raising their dividends this week.
Jun 2, 2015
Medtronic On Track with Covidien Integration
We liked Medtronic before its acquisition of Covidien, and we continue to like the company now.
Mar 5, 2015
These Valuations Are Embarrassing
Airbnb? Uber? Xiaomi? Palantir? What?
Nov 18, 2014
Medtronic Surpasses $70 Per Share
The Dividend Growth portfolio holding continues to defy gravity.
Sep 2, 2014
The Dividend Dilemma
Remember that you’re putting your hard-earned capital at risk for an income stream. Be sure to keep your guard up.
Aug 26, 2014
Price Is Almost Always Different Than Value
This key tenet behind stock market investing success is worth remembering.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.